RIGI and cancer: In keeping with previous studies showing that treatment with other RIG-I agonists induced cancer cell death mediated by immune cells, including DCs, NK cells, and CD8+ T cells [39–42], we show that i.t. injection of M8 increases the proportion of infiltrating CD45+ leukocytes.